Precipio, Inc.: insider trades · United States · SEC (Form 4)

About Precipio, Inc.

Precipio, Inc. (ticker: PRPO) is a United States-based healthcare biotechnology and diagnostics company listed on the NASDAQ Capital Market. For French-, Belgian- and Swiss-based investors, Precipio is best understood as a small-cap specialty diagnostics platform focused on cancer testing, with particular emphasis on hematologic malignancies and the reduction of misdiagnosis. The company was incorporated in Delaware in 1997 and later took its current form after a reverse-merger transaction in 2017. Its headquarters are in New Haven, Connecticut, placing it in a strong academic and medical ecosystem that supports clinical partnerships and product validation. Precipio’s business model is built around two complementary activities operating under a single reportable segment. First, the company runs pathology and diagnostic services for physicians, hospitals, and laboratories. Second, it develops and commercializes proprietary diagnostic products and reagents. Management describes this integrated structure as a way to make the service business also function as a self-funded R&D engine: clinical operations generate real-world diagnostic data, while the company uses that environment to refine, validate, and commercialize new products. Precipio operates CLIA-compliant laboratories in New Haven, Connecticut and Omaha, Nebraska, and its product-development work is centered on improving the accuracy and speed of cancer diagnostics. Key offerings include HemeScreen, IV-Cell, and related reagent and panel solutions designed for hematology and oncology workflows. These products aim to improve diagnostic precision, shorten turnaround times, and help clinicians identify blood cancers and related abnormalities more reliably. In competitive terms, Precipio occupies a niche position in a market dominated by much larger diversified diagnostics groups and other specialized lab companies. Its differentiation comes from its focus on misdiagnosis reduction, its proprietary technologies, and its collaboration-oriented operating model. The company has also referenced long-standing academic and medical relationships that support product development and market credibility. Geographically, Precipio remains primarily U.S.-focused, serving a nationwide customer base from its Connecticut and Nebraska facilities. Recent disclosures indicate a business that is still small but showing operating momentum. In its first-quarter 2026 release, Precipio reported revenue of $6.71 million, while third-quarter 2025 results had already shown year-over-year revenue growth and positive adjusted EBITDA. That said, the company remains execution-sensitive: growth depends on pathology volume, customer onboarding, reimbursement dynamics, and continued adoption of its product line. For investors, Precipio is a specialized NASDAQ-listed U.S. healthcare story with higher risk than large-cap diagnostics peers, but also with a focused niche strategy and potential operating leverage if commercialization continues to scale.